High-throughput fragment-based drug screening

Fragment screening by protein crystallography has been at the heart of medicinal chemistry developments for decades, though until recently it was dominated by industry. With significant improvements in lab and synchrotron hardware, these technologies are becoming slowly available for academic labs. My lab is pioneering these technologies within the National Cancer Institute. Using a robust pipeline for protein crystallization, compound soaking and harvesting, we can screen hundreds of fragments and obtain ligated structures from which pharmacophores can be derived. These are the first steps in a medicinal chemistry campaign, which also provide opportunities for IP generation.

Cancer metabolism

Cancer cells are incredibly resistant to typical apoptotic mechanisms, allowing them to survive and proliferate. Many of these mechanisms are linked to cellular metabolic changes. By targetting upregulated metabolic pathways and proteins in tumors, cancer cells can be sensitized and cancers better erradicated. 

Collaborative environment

All of our projects use synergistic approaches, employing organic chemistry and biophysics tools. We collaborate with scientists at X-ray radiation facilities harnessing the most cutting-edge synchrotron hardware available as well as with groups and facilities at NCI to provide translational capabilities for our medicinal chemistry campaigns. We collaborate closely with the Molecular Targets Program and the Medicinal Chemistry Accelerator.